Overview

Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy

Status:
Not yet recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

Ion deficiency anemia (IDA) is associated with poor neonatal outcomes and maternal morbidity. Iron replacement may be done with oral iron or intravenous iron, with intravenous iron being utilized later in pregnancy or if there is an inadequate response to oral iron in the first trimester. In Canada, iron sucrose has been used, however iron isomaltoside is as safe as other formulations of IV iron but can replete iron stores with a single visit. Replenishing iron stores reduces both maternal and neonatal risks and is supported by current guidelines. Iron status may play a role in depression, as well as anemia, bleeding and blood transfusion. The goal of this clinical trial: - Correct IDA with fewer visits and less impact on the healthcare system - Improve the health and well being of all pregnant women who are experiencing moderate to severe iron deficiency anemia.

Phase:

Phase 3

Details

Lead Sponsor:

Saskatchewan Health Authority - Regina Area

Collaborator:

Saskatchewan Centre for Patient-Oriented Research

Treatments:

Ferric Oxide, Saccharated
Iron
Iron isomaltoside 1000